Press "Enter" to skip to content

RELAY: Ramucirumab, erlotinib combination improves PFS in EGFR- mutated metastatic NSCLC – Healio

admin 0

RELAY: Ramucirumab, erlotinib combination improves PFS in EGFR- mutated metastatic NSCLC  Healio

CHICAGO — The addition of ramucirumab to erlotinib significantly improved the outcomes of patients with EGFR-mutated metastatic non-small cell lung cancer …

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *